LXR cardiovascular, transplant news

LXR said it will change its strategy to focus on its Cardiosol heart preservation solution, its Elirex small molecule apoptosis suppressor to treat myocardial infarction and its secreted apoptosis-related proteins. The company said that other programs will be either out-licensed or discontinued, and that it has enough cash to continue through the first quarter of 1999. ...